Camp Lejeune cancer lawsuit

Camp Lejeune Cancer Study To Be Released By The End Of January 2024

The study may have been suppressed by the government because it expands the number of types of cancer caused by Camp Lejeune water contamination

Sunday, January 21, 2024 - In what may be a breakthrough in defining the types of cancer that qualify for Camp Lejeune water cancer benefits, the government has agreed to release its comprehensive Camp Lejeune water contamination cancer study to the public by the end of January 2024. The study could link Camp Lejeune water contamination more types of water contamination cancer than the Navy had previously been willing to admit to. Releasing the study's findings could double or triple the number of claims that could be made seeking water contamination benefits and give new life to lawsuits that have been filed seeking compensation for personal injury and wrongful death. More than 1,400 lawsuits and more than 130,000 administrative claims have been filed with the government alleging drinking the water at Camp Lejeune from 1953 to 1987 caused them to develop cancer. cancer. In response to the slow administrative process, the government recently initiated the Elective Option which pays a lump sum of up to $550,000 if a person had a specific type of cancer. Types of cancer on the Elective Option's presumptive list are based on the Agency for Toxic Substances and Disease Registry report. "Claimants with the following medical conditions may be eligible for an expedited resolution under the Elective Option: Kidney Cancer, Non-Hodgkin's Lymphoma, Leukemia, Bladder Cancer, Multiple Myeloma, Liver Cancer, Parkinson's Disease, Kidney Disease, and Systemic Sclerosis / Scleroderma," according to Navy.mil.

At the core of Camp Lejeune Justice Act claims are the specific and limited number of types of cancer and other illnesses that may be presumed to have caused cancer. Claims have been filed since August 2022 and the Navy has six months to address each claim. After the six months have passed, the claimant is free to file a lawsuit in the Eastern District of North Carolina. It had been more than one year and not a single claim had been decided upon. The Navy and Department of Justice found that thousands of fraudulent claims had been made and increased their diligence to detect bad claims slowing down the process even more. The government stated they would automatically approve any administrative claims if the claimant was already receiving VA benefits for Camp Lejeune water Attorneys for claimants with various other types of cancer are furious that their claims may be rejected because one scientific study conducted by the government may have been suppressed.

The Camp Lejeune Justice Act, enacted to address the contamination crisis at the United States Marine Corps Base Camp Lejeune, signifies a landmark legislative effort. This pivotal law aims to provide justice and compensation to military personnel and their families who suffered adverse health effects due to exposure to toxic substances in the base's water supply. By holding accountable those responsible for the contamination, the Act strives to ensure that affected individuals receive the support they deserve. Its implementation underscores the government's commitment to rectifying environmental injustices, and safeguarding the rights and well-being of those who have selflessly served their country at Camp Lejeune.

Information provided by CampLejeuneJusticeActClaim.com, a website devoted to providing news about Camp Lejeune Justice Act Claim, including a free no-cost, no-obligation Camp Lejeune Justice Act Claim.

More Recent Camp Lejeune Water Lawsuit News:

View all Camp Lejeune Justice Act Claim News

No-Cost, No-Obligation Claim Review for Persons or Families of Persons Who Developed Cancer After Spending 30 Days or More at Camp Lejeune between 1953 and 1988

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.


Privacy Notice: This site uses cookies for advertising, analytics and to improve our site services. By continuing to use our site, you agree to our use of cookies. For more information, see our cookie and privacy policy.